REDWOOD CITY, Calif.,
Nov. 7, 2019 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) announced that its
stockholders voted to approve the company's proposed combination
with Exact Sciences Corp (NASDAQ: EXAS) at a special meeting held
earlier today.
As previously announced, on July 29,
2019, Genomic Health and Exact Sciences entered into the
merger agreement by which Exact Sciences will acquire Genomic
Health in a cash and stock transaction. With the receipt of
the required stockholder approval, Genomic Health and Exact
Sciences expect to close the transaction on Friday, November 8 subject to satisfaction of the
remaining customary closing conditions.
Final vote tallies from the Genomic Health special meeting of
stockholders are subject to certification by the Company's
inspector of elections and will be included in a report to be filed
by the Company with the Securities and Exchange Commission (the
"SEC").
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic data
into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to
guide treatment decisions for over 1 million cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
Oncotype DX® AR-V7 Nucleus
Detect™ test. The company is based
in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains statements, including statements
regarding the merger that are forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor"
created thereby. Forward-looking statements, which are based on
certain assumptions and describe future plans, expectations and
events, can generally be identified by the use of forward-looking
terms such as "believe," "expect," "may," "will," "should,"
"would," "could," "seek," "intend," "plan," "anticipate" or other
comparable terms. All statements other than statements of
historical facts included in this press release regarding the
expected closing of the merger are forward-looking statements.
Forward-looking statements are neither historical facts nor
assurances of future performance or events. Instead, they are based
only on current beliefs, expectations and assumptions regarding
future business developments, future plans and strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of Genomic Health's control. Actual results,
conditions and events may differ materially from those indicated in
the forward-looking statements. Therefore, you should not rely on
any of these forward-looking statements. Important factors that
could cause actual results, conditions and events to differ
materially from those indicated in the forward-looking statements
include, among others, the following: the ability of the parties to
satisfy the remaining closing conditions in order to close the
proposed merger with Exact Sciences Corporation and other risks as
detailed from time to time in Genomic Health's reports filed with
the SEC, including its annual report on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K and other
documents filed with the SEC.
There can be no assurance that the merger or any other
transaction described will in fact be completed in the manner
described or at all. Any forward-looking statement speaks only as
of the date on which it is made, and Genomic Health assumes no
obligation to update or revise such statement, whether as a result
of new information, future events or otherwise, except as required
by applicable law. Readers are cautioned not to place undue
reliance on any of these forward-looking statements.
GHDX-F
View original content to download
multimedia:http://www.prnewswire.com/news-releases/genomic-health-stockholders-approve-proposed-acquisition-by-exact-sciences-300954179.html
SOURCE Genomic Health, Inc.
